Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
|
|
- Cameron Norris
- 6 years ago
- Views:
Transcription
1 Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors that guide selection based on individualized patient characteristics. Disclosures Diana Isaacs has nothing to disclose. Diabetes: The Stats Cases of diabetes million people in the U.S. (9.3% population) New cases: 1.4 million Americans/year On : 28.7% Accessed April 9 th, th, 2016 Normal Release Individuals without diabetes bolus occurs in the first 10 minutes after eating Blood sugar 1910: Discovery of 1982: 1953: Humulin R, Lente Humulin N History of 1996: Rapid acting lispro 2000: Long acting analog; glargine 2005: detemir 2015: U-300 glargine U-100/ degludec lispro 2017: Fiasp in Canada: ultra rapid Basal Basal is released every 12 minutes Meal Meal Meal Blood sugar goes up after eating 1950: NPH 1976: 1st pump 1994: R U-500 Human 2000: aspart 2004: glulisine 2014: inhaled 2016: GLP-1 combos, biosimilar glargine 1
2 5/23/17 ADA Treatment Algorithm So Much Regular Novolin R, Humulin R Neutral protamine hagedorn (NPH) Novolin N, Humulin N Pre-mixed Lispro 70/30, 75/25, 50/50 Aspart 70/30, Ryzodeg 70/30 Long-acting Glargine (Lantus, Basaglar ), Detemir (Levemir ), Degludec (Tresiba ) Rapid-acting Inhaled Lispro (Humalog ), Aspart (Novolog ), Glulisine (Apidra ) Concentrated Humulin R U-500 Glargine U-300 (Toujeo ) Degludec (Tresiba ) Lispro (Humalog ) Diab Care :S52-S59 Choice of Basals NPH Levemir Toujeo Choice of Bolus Tresiba U-100 Lantus Tresiba /GLP-1 RA Combos Lixisenatide + glargine in a fixed-ratio pen (Soliqua ) - Daily dose range: units corresponding to lixisenatide 5-20mcg Novolog Humalog U-100 Humalog Liraglutide + degludec in a fixed-ratio pen (Xultophy ) - Max dose 50 units corresponding to liraglutide 1.8mg Apidra Afrezza Regular 2
3 New Drug Approvals Long-acting - degludec (Tresiba U-100 ) - degludec/aspart 70/30 (Ryzodeg ) - glargine U-100 (Basaglar ) Concentrated - degludec (Tresiba ) - glargine U-300 (Toujeo ) - Humulin R U-500 Kwikpen - lispro (Humalog ) Degludec (Tresiba ) Mechanism of action - After injection, Ideg dihexamers join together creating long, soluble multiheximer chains that prolong duration of action Available in U-100,, and aspart 70/30 combo (Ryzodeg ) kwik pens - Ryzodeg not available in U.S. Tresiba Pacakge Insert, NovoNordisk, 2015 Tresiba Clinical Data Study Design Intervention Results: Efficacy 52 weeks, controlled, openlabel, multinational, parallel design, treat-totarget, noninferiority trial 52 weeks, controlled, openlabel, treat-totarget, multinational, noninferiority trial Adults with T2DM randomized to degludec (n=773) or glargine (n=257) both in combination with metformin. Adults with T2DM randomized to degludec (n = 755) or glargine (n=251) both in combination with aspart before meals, +/- metformin and/or pioglitazone. degludec and glargine decreased mean A1C by 1.06 and 1.19%, respectively (95% CI 0.04 to 0.22%), meeting criteria for non-inferiority. Nocturnal hypoglycemia and severe hypoglycemia occurred less with degludec (p < 0.05). degludec and glargine decreased mean A1C by 1.10 and 1.18%, respectively. (95% CI 0.05 to 0.21%), meeting criteria for non-inferiority. Rates of overall hypoglycemia and nocturnal hypoglycemia were lower with degludec. Diabetes Care 35: , Lancet 379: , degludec Tresiba Vs. Lantus Longer half-life More forgiving if a dose is missed True once daily dosing Max 80 (U-100)-160 () units per injection Ability to mix with aspart No vial available glargine Easier to treat hypoglycemia Quicker to make dose adjustments Max 80 (pen) to 100 units (vial) per injection More years of experience Cheaper alternative basaglar available Both available in combo with GLP-1 RA Glargine U-300 (Toujeo ) Toujeo Clinical Data Offers a smaller depot surface area, leading to a reduced rate of absorption Provides flatter and prolonged PK and PD profiles and more consistency Structurally identical to glargine May need higher doses than Lantus Longer half-life Longer duration of action Limited to 80 units/dose via pen, no vial Product information for Toujeo. Sanofi-Aventis U.S. LLC. Bridgewater, NJ September Toujeo Clinical Data Available at: Accessed 11/15/16 3
4 Glargine U-100 (Basaglar ) Identical amino acid sequence to glargine (Lantus ) - Different excipients Demonstrated non-inferiority to Lantus Available in 3mL Kwikpen, no vial Not technically approved as a biosimilar - Follow on abbrev approval process Cheaper price Basaglar Clinical Data Study Design Intervention Results: Efficacy/Safety Element 1 52 weeks, open-label Element 2 24 weeks, controlled, double-blind Adults with T1DM randomized to Lantus (n=267) or Basaglar (n=257) both in combination with lispro. Adults with T2DM randomized to Lantus (n 380) or Basaglar (n=376) both in combination with 2 or more oral anti-diabetes agents. Lantus and basaglar decreased mean A1C by 0.46% and 0.35%, respectively (95% CI to 0.219, P>0.05%), meeting criteria for non-inferiority. Similar adverse effects between group, 4% severe hypoglycemia Mean A1c change in both groups was 1.3% (CI: to , P>0.05) meeting criteria for noninferiority. Similar adverse effects between group, <1% severe hypoglycemia Basaglar [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. Diabetes Obes Metab Aug;17(8): Diabetes Obes Metab Aug;17(8): Humulin R U-500 Pen FDA approved Jan, x concentration compared to U-100 Delivers up to 300 units in a single injection Acts like intermediate acting Most ideal for patients with resistance - Patients injecting >200 units/day Unlike the vial, no dosing conversions Vial is still available New U-500 syringe now available Inhaled human inhalation power Onset: minutes, Peak: 1 hour, DOA: 3 hours Available in prepackaged blister packs containing 15 cartridges Each blister pack, once opened, is good for 10 days Inhaler must be changed everydays Warnings Acute bronchospasm in patients with asthma or COPD Contraindicated with chronic lung diseases Before initiating, perform a detailed medical history, physical exam and spirometry Side effects: hypoglycemia, cough, throat pain package insert Fiasp Meal time aspart formulation with niacinamide (vitamin B3) - Faster absorption - Quicker onset Inject 2 min before start of meal up to 20 min after Duration of action 10% shorter vs. Novolog Available in Canada (not U.S.) fiasp-product-monograph.pdf 4
5 Profiles Cornell, S. ICHP 2016 Annual Meeting Property Long-Acting Comparison Glargine (U-300) Toujeo Glargine (U-100) Lantus Degludec (U-100) Tresiba Degludec () Tresiba Humulin R U-500 KwikPen Concentration 300 units/ml 100 units/ml 100 units/ml 200 units/ml 500 units/ml Onset 6 hours 4-5 hours 1-2 hours 1-2 hours 30 min Duration of hours 24 hours > 42 hours > 42 hours hours Half-life ~ 19 hours ~ 12 hours 25 hours 25 hours 4.5 hours Time to Steady State Units per pen Max units injected/dose 5 days 1 day 3 days 3 days 1 day 450 units in 1.5mL 300 units in 3mL 300 units in 3mL 600 units in 3mL 1500 units in 3 ml 80 units 80 units 80 units 160 units 300 units Dial 1 unit 1 unit 1 unit 2 units 5 units Pen or Vial? Pen Pen/vial Pen Pen Pen/vial Expiration 42 days 28 days 56 days 56 days 28 days pen 40 days vial Detail-Document; Pharmacist's Letter 2015; 31(4):310402, Lantus pacakge insert, Diabetes Care 2015 Apr; 38(4): , Tresiba Pacakge Insert, NovoNordisk, 2015 Levemir, NPH, Regular Property Determir Levemir NPH Humulin N, Novolin N Regular Humulin R, Novolin R Type Long acting Intermediate acting Short acting Concentration 100 units/ml 100 units/ml 100 units/ml Onset hours 1-2 hours 30 minutes Peak None 4-10 hours 3 hours Duration of hours 14 hours 8 hours Timing 1-2x daily 1-2x daily 30 minutes before meals Cloudy or Clear? Clear Cloudy Clear Pen or Vial? Pen/vial Pen/vial Vial Expiration 42 days 31 days 31 days Detail-Document; Pharmacist's Letter 2015; 31(4):310402, Lantus pacakge insert, Diabetes Care 2015 Apr; 38(4): , Tresiba Pacakge Insert, NovoNordisk, 2015 Property Lispro Humalog Rapid-Acting Comparison Lispro Humalog () Aspart Novolog Glulisine Apidra Inhaled Onset min min min 25 min min Duration of Meal Timing hours hours 3-5 hours hours 160 min SC up to 15 min before or immediately after meal SC up to 15 min before or immediately after meal SC 5-10 min before meals SC within 15 min before or 20 min after starting meal Units per pen 300 units in 3mL 600 units in 3mL 300 units in 3mL 300 units in 3mL NA Max units injected/dose Inhaled at beginning of meal 60 units 60 units 60 units 80 units 4,8,12 unit cartridges Pens/box NA Available as vial? Yes No Yes Yes NA Expiration 28 days 28 days 28 days 28 days 3 days Detail-Document; Pharmacist's Letter 2015; 31(4): Accessed Sept 5 th, Accessed Sept 5th, 2016 Tips and Tricks Long-acting with rapid-acting (or pump) best for T1DM or -dependent T2DM NPH-great for pregnancy and steroid induced diabetes Regular, NPH, Novolin 70/30 are available OTC and cheap - Co-pay cards available for the newer s 70/30 and other combos good for limiting to 2 injections/day, but less dose flexibility All can cause weight gain and hypoglycemia 5
6 Selection Which of the following s are available in a U-300 formulation? Cost Adherence Formulary A. detemir B. glargine Onset of Hypoglycemia Duration of C. regular D. degludec Volume Weight Gain Patient Preference Which of the following s are available in a vial? Key Points New s offer more treatment options A. Humulin R U-500 B. degludec U-100 (Tresiba ) C. glargine (Toujeo ) D. glargine (Basalgar ) The goal is to mimic the body s natural production of (basal/bolus) Several factors guide selection including side effect profile, onset/duration of action, volume of injection, and patient preferences Navigating New s Diana Isaacs isaacsd@ccf.org 6
8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations
UNRAVELING THE CROWED INSULIN SCENE A Practical Overview of Insulin Focusing on New Insulin Preparations Patricia Garnica MS, ANP-BC, CDE, CDTC North Shore University Hospital, Manhasset, N.Y. October
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationConverting lantus to humalog 75 25
P ford residence southampton, ny Converting lantus to humalog 75 25 This page includes the following topics and synonyms: Insulin Dosing in Type 2 Diabetes, Insulin Dosing in Type II Diabetes. Thiazide
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationLantus to levemir conversion
Lantus to levemir conversion The Borg System is 100 % Lantus to levemir conversion 16-6-2005 Ask the Expert on... Lantus Conversion. Karen Shapiro, PharmD, BCPS. Disclosures. June 16, 2005. Question. Would
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationDiabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services
Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationDrug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More information8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy
Insulin Basics Anabolic hormone involved in metabolism Following carbohydrate ingestion insulin release is stimulated Suppresses hepatic glucose production Stimulates peripheral glucose uptake Commercially-available
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationInsulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018
Insulins: Prices, Rebates, and Other Factors Influencing Costs May 2018 Introduction: Types of Insulin Types of Insulin Rapid-acting: Usually taken before a meal to cover the blood glucose elevation from
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationINSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationConversion from lantus to tresiba
Conversion from lantus to tresiba Search dosages for Diabetes Type 2 and Diabetes Type 1; plus renal, liver and. Forecast your health care. Every time you have a symptom or are diagnosed of a condition,
More informationDisclosures. Learning Objectives 4/26/2017
Implementation of a quality improvement initiative to ensure the safe transition from prior-to-admission concentrated insulins to a formulary insulin regimen ERICA J. RHEIN, PHARMD PGY1 PHARMACY PRACTICE
More informationOHSU Drug Effectiveness Review Project Summary Report Long-Acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationToujeo conversion to lantus
Detailed dosage guidelines and administration information for Toujeo (insulin glargine). Includes dose adjustments, warnings. The TOUJEO SoloStar prefilled pen has been specifically designed for TOUJEO,
More informationConversion of lantus to toujeo
Conversion of lantus to toujeo Search The dosing information for Toujeo recommends decreasing the total insulin dose to 80% of the daily requirement of Toujeo when switching from to. Watch a video to learn
More informationPremixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s
Premixed Insulin for Type 2 Diabetes a gu i d e f o r a d u lt s March 2009 What This Guide Covers / 2 Type 2 Diabetes / 3 Learning About Blood Sugar / 4 Learning About Insulin / 5 Comparing Medicines
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationInsulin Management and Advancing Practice of the Registered Dietitian Nutritionist (RDN) in Diabetes Care
Insulin Management and Advancing Practice of the Registered Dietitian Nutritionist (RDN) in Diabetes Care Patricia Davidson, DCN, RDN, CDE, LDN, FAND West Chester University of Pennsylvania West Chester,
More informationSpending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices
Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices Authors: Jean Fuglesten Biniek William Johnson January 2019 Insulin Prices Were the Primary Driver of Rapid
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationGuide for Storage of Insulin
Guide for Storage of Insulin Every effort is made to assure the accuracy of the attached information. This information is not intended to be used as a tool to prescribe medication or provide other clinical
More informationInsulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination. Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM
Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM University of Mississippi School of Pharmacy Joshua J. Neumiller, Pharm.D., CDE, FAADE,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other INSULIN REGULAR, HUMAN AFREZZA 37619, 37622, 37623, 38923, 37624, 42833, 38918, 37621 GUIDELINES FOR USE 1. Is the member currently taking the requested medication
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationDiana McNeill MD, FACP Professor of Medicine Duke University Medical Center. Disclosures
Insulin Therapy in Diabetes So Many Choices Diana McNeill MD, FACP Professor of Medicine Duke University Medical Center Disclosures Mytonomy-consultant Quantia webinars Acknowledgements: Dr. Sue Kirkman-UNC-
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationToujeo to lantus conversion
P ford residence southampton, ny Toujeo to lantus conversion Chart of all the available insulins and their properties including onset of action, duration of action, available forms (vials and pens), peak
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationManagement of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth
Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will
More informationInsulin Drug Class Update
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationInsulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )
Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Toujeo uses the same
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationDegludec lantus conversion
Degludec lantus conversion Search embarazadas con elevado riesgo de enfermedad tiroidea usando la. There are various possible causes of a high blood sugar level in the morning: The Dawn Phenomenon which
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationInsulin Management. By Susan Henry Diabetes Specialist Nurse
Insulin Management By Susan Henry Diabetes Specialist Nurse The Discovery of Insulin - 1921 - Banting & Best University Of Toronto Discovered hormone insulin in pancreatic extract of dog - Marjorie the
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationAll Things Insulin: Dosing, Monitoring, Titrating, Transitioning
All Things Insulin: Dosing, Monitoring, Titrating, Transitioning Target Audience: Pharmacists ACPE#: 0202-0000-18-052-L01-P Activity Type: Application-based Disclosures Stuart Haines declares that he has
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationModule 5. Understanding Insulin Therapy
Module 5. Understanding Insulin Therapy EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better able to: 1. Define the basic physiologic concept of basal-bolus insulin; 2.
More informationSafe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System Objectives To be
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationORAL AGENT FAILURE AND GLP1 FAILURE TO REACH GOALS WHERE DO WE GO FROM HERE
ORAL AGENT FAILURE AND GLP1 FAILURE TO REACH GOALS WHERE DO WE GO FROM HERE key objectivies UNDERSTAND HOW TO DEFINE ORAL and INGECTABLE AGENT FAILURES understand benefit of QUADRUPLE oral agents vs
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More information4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures
Flexible Intensive Insulin Therapy (FIIT) in People with Type Diabetes: A Viable Option Kim Bisanz, MFCS, RDN, LDN, CDE Minnesota Academy of Nutrition & Dietetics Annual Meeting April 19, 18 18 MFMER slide-1
More informationInsulin Cases: Inpatient and Outpatient
Insulin Cases: Inpatient and Outpatient Susan Cornell, BS, PharmD., CDE, FAPhA, FAADE Associate Director, Office of Experiential Education Associate Professor of Pharmacy Practice Midwestern University
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationAntidiabetic Agents CHAPTER BIGUANIDES
ajt/shutterstock, Inc. CHAPTER 2 Antidiabetic Agents Charles Ruchalski, PharmD, BCPS BIGUANIDES For newly diagnosed patients with type 2 diabetes, the biguanide metformin is the drug of choice for initial
More informationInsulin for Adults with Type 2 Diabetes
rth Central London Joint Formulary Committee Insulin for Adults with Type 2 Diabetes Disclaimer This guideline is registered at rth Central London (NCL) Joint Formulary Committee (JFC) and is intended
More informationWhat is shelf life of lantus
What is shelf life of lantus Search 6-6-2011 I've been told Lantus looses some of it's effectiveness after 30. Levemir has a 42 day shelf life after opening. 5 Reasons to Join Diabetic Connect;. Lantus
More informationADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services
1.19.18 Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services DISCLOSURES 1. No financial incentives 2. Volunteer Positions 1. National Certification Board
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationHow to Fight Diabetes and Win. Diabetes. Medications
How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to
More information!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((
!"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationLevemir vs lantus dose conversion
Levemir vs lantus dose conversion The Borg System is 100 % Levemir vs lantus dose conversion Converting patients from insuline glargine U-100 to insulin detemir. Converting from insulin glargine U-100.
More informationHow to Switch Between Insulin Products
Detail-Document #251005 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2009 ~ Volume 25 ~ Number 251005 How to Switch Between Insulin
More informationInsulin Drug Class Update
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information